Header Logo

Connection

Carl Maki to Humans

This is a "connection" page, showing publications Carl Maki has written about Humans.
Connection Strength

1.065
  1. CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor. Sci Rep. 2023 09 27; 13(1):16271.
    View in: PubMed
    Score: 0.050
  2. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. Cancer Biol Ther. 2022 12 31; 23(1):65-75.
    View in: PubMed
    Score: 0.047
  3. RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 01 20; 12(1):1049.
    View in: PubMed
    Score: 0.044
  4. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. J Mol Cell Biol. 2021 09 11; 13(6):433-444.
    View in: PubMed
    Score: 0.043
  5. Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer. Cancer Biol Ther. 2020 11 01; 21(11):1033-1040.
    View in: PubMed
    Score: 0.040
  6. The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells. J Biol Chem. 2019 06 07; 294(23):9186-9197.
    View in: PubMed
    Score: 0.037
  7. JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. Oncogene. 2019 07; 38(28):5643-5657.
    View in: PubMed
    Score: 0.036
  8. Alpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a. Cancer Biol Ther. 2019; 20(3):252-260.
    View in: PubMed
    Score: 0.035
  9. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a. J Mol Cell Biol. 2018 08 01; 10(4):331-340.
    View in: PubMed
    Score: 0.035
  10. DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a. Cancer Biol Ther. 2018 06 03; 19(6):465-474.
    View in: PubMed
    Score: 0.034
  11. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer Biol Ther. 2017 Nov 02; 18(11):895-903.
    View in: PubMed
    Score: 0.032
  12. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget. 2016 May 10; 7(19):27511-26.
    View in: PubMed
    Score: 0.030
  13. Modeling the Etiology of p53-mutated Cancer Cells. J Biol Chem. 2016 May 06; 291(19):10131-47.
    View in: PubMed
    Score: 0.029
  14. p53-regulated autophagy is controlled by glycolysis and determines cell fate. Oncotarget. 2015 Sep 15; 6(27):23135-56.
    View in: PubMed
    Score: 0.028
  15. Novel roles for p53 in the genesis and targeting of tetraploid cancer cells. PLoS One. 2014; 9(11):e110844.
    View in: PubMed
    Score: 0.027
  16. Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells. Cancer Lett. 2014 Oct 28; 353(2):290-300.
    View in: PubMed
    Score: 0.026
  17. The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT. J Biol Chem. 2014 Aug 01; 289(31):21694-705.
    View in: PubMed
    Score: 0.026
  18. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1. Cancer Biol Ther. 2014; 15(12):1600-12.
    View in: PubMed
    Score: 0.025
  19. Two 4N cell-cycle arrests contribute to cisplatin-resistance. PLoS One. 2013; 8(4):e59848.
    View in: PubMed
    Score: 0.024
  20. Glucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase Ce. J Biol Chem. 2012 Aug 24; 287(35):29825-36.
    View in: PubMed
    Score: 0.023
  21. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene. 2011 Nov 17; 30(46):4678-86.
    View in: PubMed
    Score: 0.021
  22. Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des. 2011; 17(6):560-8.
    View in: PubMed
    Score: 0.021
  23. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells. J Cell Biochem. 2010 Dec 01; 111(5):1280-90.
    View in: PubMed
    Score: 0.020
  24. Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells. J Biol Chem. 2010 Jul 23; 285(30):23105-14.
    View in: PubMed
    Score: 0.020
  25. Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther. 2010 Apr; 9(4):895-905.
    View in: PubMed
    Score: 0.019
  26. Puromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and Proteasomes. BMC Cell Biol. 2009 May 01; 10:32.
    View in: PubMed
    Score: 0.018
  27. Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res. 2008 Oct 15; 68(20):8260-8.
    View in: PubMed
    Score: 0.018
  28. Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells. Oncogene. 2008 Sep 18; 27(42):5567-77.
    View in: PubMed
    Score: 0.017
  29. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J Biol Chem. 2007 May 11; 282(19):14616-25.
    View in: PubMed
    Score: 0.016
  30. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. J Biol Chem. 2007 May 11; 282(19):14626-34.
    View in: PubMed
    Score: 0.016
  31. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity. Mol Cancer. 2006 Dec 06; 5:68.
    View in: PubMed
    Score: 0.015
  32. P53 gene alterations identified in classical Hodgkin's lymphoma cell lines. Leuk Lymphoma. 2006 Sep; 47(9):1734-5.
    View in: PubMed
    Score: 0.015
  33. Control of p53 nuclear accumulation in stressed cells. FEBS Lett. 2005 Sep 12; 579(22):4978-84.
    View in: PubMed
    Score: 0.014
  34. Cdk2-dependent Inhibition of p21 stability via a C-terminal cyclin-binding motif. J Biol Chem. 2005 Aug 12; 280(32):29282-8.
    View in: PubMed
    Score: 0.014
  35. A link between p73 transcriptional activity and p73 degradation. Oncogene. 2004 May 13; 23(22):4032-6.
    View in: PubMed
    Score: 0.013
  36. Physical and functional interactions between PML and MDM2. J Biol Chem. 2003 Aug 01; 278(31):29288-97.
    View in: PubMed
    Score: 0.012
  37. Stability and ubiquitination of the tumor suppressor protein p53. Methods Mol Biol. 2003; 223:27-38.
    View in: PubMed
    Score: 0.012
  38. Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles. Proc Natl Acad Sci U S A. 2022 09 20; 119(38):e2205454119.
    View in: PubMed
    Score: 0.012
  39. MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J Biol Chem. 2001 Nov 30; 276(48):45255-60.
    View in: PubMed
    Score: 0.011
  40. Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents. FEBS Lett. 2001 Feb 16; 490(3):196-201.
    View in: PubMed
    Score: 0.010
  41. MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene. 2000 Nov 30; 19(51):5892-7.
    View in: PubMed
    Score: 0.010
  42. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol. 2000 Sep; 2(9):569-73.
    View in: PubMed
    Score: 0.010
  43. Role and regulation of p53 during an ultraviolet radiation-induced G1 cell cycle arrest. Cell Growth Differ. 2000 Mar; 11(3):149-56.
    View in: PubMed
    Score: 0.010
  44. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem. 1999 Jun 04; 274(23):16531-5.
    View in: PubMed
    Score: 0.009
  45. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol. 1997 Jan; 17(1):355-63.
    View in: PubMed
    Score: 0.008
  46. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 1996 Jun 01; 56(11):2649-54.
    View in: PubMed
    Score: 0.007
  47. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222.
    View in: PubMed
    Score: 0.007
  48. The Drosophila melanogaster RPS17 gene encoding ribosomal protein S17. Gene. 1989 Jul 15; 79(2):289-98.
    View in: PubMed
    Score: 0.005
  49. Overexpression of Bcl-2 differentially restores development of thymus-derived CD4-8+ T cells and intestinal intraepithelial T cells in IFN-regulatory factor-1-deficient mice. J Immunol. 2001 Jun 01; 166(11):6509-13.
    View in: PubMed
    Score: 0.003
  50. Transcriptional activation of bovine mimecan by p53 through an intronic DNA-binding site. Biochim Biophys Acta. 2001 Feb 16; 1517(3):333-8.
    View in: PubMed
    Score: 0.003
  51. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 1999 Dec 15; 59(24):6046-51.
    View in: PubMed
    Score: 0.002
  52. Absence of a radiation-induced first-cycle G1-S arrest in p53+ human tumor cells synchronized by mitotic selection. Cancer Res. 1998 May 01; 58(9):2036-41.
    View in: PubMed
    Score: 0.002
  53. Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. Cancer Res. 1995 May 01; 55(9):1842-6.
    View in: PubMed
    Score: 0.002
  54. A cDNA encoding human ribosomal protein S24. Gene. 1990 Jul 16; 91(2):293-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.